Calcipotriol
Based on 46 publication(s) in Google Scholar
Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 112965-21-6
- Formula: C27H40O3
- Molecular Weight:412.60
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications Citing Use of MedChemExpress (MCE) Calcipotriol
More- Immunity. 2024 May 14:S1074-7613(24)00227-9. [Abstract]
- Bioact Mater. 2025 Nov 25:57:646-659. [Abstract]
- Adv Funct Mater. 2025 May 27.
- Nat Commun. 2023 Apr 29;14(1):2478. [Abstract]
- Sci Adv. 2024 Oct 4;10(40):eadp5332. [Abstract]
- J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. [Abstract]
- J Exp Med. 2021 Dec 6;218(12):e20210639. [Abstract]
- Cell Death Dis. 2021 Sep 24;12(10):871. [Abstract]
- J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13733. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Apr 4;120(14):e2221255120. [Abstract]
- Int J Biol Macromol. 2025 Aug 21;323(Pt 1):147047. [Abstract]
- Acta Pharmacol Sin. 2025 Apr;46(4):904-921. [Abstract]
- Acta Pharmacol Sin. 2023 Jan;44(1):178-188. [Abstract]
- Phytomedicine. 2025 Oct 20:148:157425. [Abstract]
- Phytomedicine. 2025 Apr 7:141:156737. [Abstract]
- Free Radic Biol Med. 2025 Nov:239:540-551. [Abstract]
- J Transl Med. 2025 Jul 10;23(1):768. [Abstract]
- Cell Rep. 2023 Nov 13;42(11):113430. [Abstract]
- Phytother Res. 2025 Nov 14. [Abstract]
- Cell Mol Life Sci. 2024 Dec 25;82(1):14. [Abstract]
- J Invest Dermatol. 2025 Aug;145(8):1930-1945.e3. [Abstract]
- J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1. [Abstract]
- J Invest Dermatol. 2024 Jun 13:S0022-202X(24)01735-4. [Abstract]
- J Invest Dermatol. 2024 Jan;144(1):53-62.e2. [Abstract]
- J Invest Dermatol. 2025 Feb;145(2):312-322.e9. [Abstract]
- Biochem Pharmacol. 2025 Jun 24:240:117059. [Abstract]
- J Ethnopharmacol. 2026 May 10:362:121364. [Abstract]
- J Ethnopharmacol. 2025 Aug 29:352:120267. [Abstract]
- J Ethnopharmacol. 2024 May 23:326:117883. [Abstract]
- Int J Pharm. 2025 Jan 7:125190. [Abstract]
- Int J Mol Sci. 2017 Dec 19;18(12). pii: E2764. [Abstract]
- Front Pharmacol. 2024 Aug 27:15:1413513. [Abstract]
- Front Pharmacol. 2020 Mar 31;11:200. [Abstract]
- Eur J Pharmacol. 2026 Mar 28:1019:178729. [Abstract]
- Int Immunopharmacol. 2023 May:118:110005. [Abstract]
- Nanomedicine. 2017 May;13(4):1473-1482. [Abstract]
- J Inflamm Res. 2025 Jun 17:18:7907-7919. [Abstract]
- J Integr Med. 2025 May;23(3):309-319. [Abstract]
- Virol Sin. 2024 Aug 19:S1995-820X(24)00134-2. [Abstract]
- Sci Rep. 2025 Jul 21;15(1):26432. [Abstract]
- Cytokine. 2023 Nov:171:156382. [Abstract]
- Med Hypotheses. 2022 Feb:159:110752. [Abstract]
- Res Sq. 2026 Jan 12.
- SSRN. 2025 Dec 30.
- bioRxiv. 2020 Jul.
- Patent. US20150283231A1.
-
IHC
-
IF
-
IF
-
IF
-
IHC
Biological Activity
Vitamin D receptor[1]
When NHEK cells are not stimulated with IL-17A or IL-22, Calcipotriol slightly enhances (0.2 nM) IL-8 mRNA expression or has no effect (2-20 nM). The addition of IL-17A and IL-22 markedly increased the mRNA expression of IL-8, confirming our previous study. This enhanced IL-8 mRNA expression is suppressed by Calcipotriol at 2, 20 and 40 nM in a dose dependent manner[1]. Treatment of natural killer (NK) cells with drugs modulates their expression of NK cytotoxicity receptors or KIR. Human NK cells are pre-treated with 100, 10 or 1 ng/mL of 1,25(OH)2D3, Calcipotriol or FTY720 for 4 h. All three concentrations of 1,25(OH)2D3, Calcipotriol and FTY720 significantly up-regulate the expression of NKp30 on the surface of NK cells after 4 h incubation[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 112965-21-6
-
Appearance Solid
-
Molecular Weight 412.60
-
Formula C27H40O3
-
Color White to off-white
-
SMILES
C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](/C=C/[C@H](C4CC4)O)C)CCC/2)[H])O)O
-
Synonyms
MC 903; Calcipotriene
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (46)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation. [Abstract]2024 May 14:S1074-7613(24)00227-9. PMID: 38772365 -
Bioact Mater
Food-derived β-lactoglobulin nanofibrils: An efficacy, safe, and scalable solution to overcome oral insulin delivery challenges. [Abstract]2025 Nov 25:57:646-659. PMID: 41377894 -
-
Nat Commun
Hydrogel dressing integrating FAK inhibition and ROS scavenging for mechano-chemical treatment of atopic dermatitis. [Abstract]2023 Apr 29;14(1):2478. PMID: 37120459 -
Sci Adv
N6-methyladenosine modification-tuned lipid metabolism controls skin immune homeostasis via regulating neutrophil chemotaxis. [Abstract]2024 Oct 4;10(40):eadp5332. PMID: 39356764
Calcipotriol purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Oct 4;10(40):eadp5332. [Abstract]
Immunofluorescence staining of ELOVL6 in the MC903-treated skin from WT or cKO mice (I) or from C57BL6/J mice with MP3C or EtOH application (J). For the MC903-induced AD mouse model, 1 nmol of Calcipotriol (MC903), dissolved in 10 μl of ethanol, was applied daily to the ears of 7-week-old mice. For dorsal application, 4 nmol of MC903, dissolved in 40 μl of ethanol, was applied daily to the backs of the mice for the specified duration.
-
J Allergy Clin Immunol
IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. [Abstract]2023 Mar;151(3):737-746.e6. PMID: 36410530
Calcipotriol purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. [Abstract]
A significant number of infiltrating cells express both IL-31 (green) and MOMA-2 (red) in Calcipotriol (MC903)-treated mice.
Calcipotriol purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. [Abstract]
Immunofluorescence staining. MC903 (Calcipotriol; 2 nmol/25 μL ethanol, applied to the earlobes once daily for 9 consecutive days)-treated mice show significant positive staining reactions for TSLP (green) at the epidermis (Fig, B) and periostin (green) in the dermis (Fig, C).
Calcipotriol purchased from MedChemExpress. Usage Cited in: J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. [Abstract]
Macroscopic and histopathological findings. Treatment of the earlobes with MC903 (Calcipotriol; 2 nmol/25 μL ethanol, applied to the earlobes once daily for 9 consecutive days) induces AD-like skin inflammation (left panel) with histopathological hyperkeratosis and acanthosis, accompanied by massive infiltrates in the dermis (middle panel) and TUG8+ basophils (red) (right panel).
-
J Exp Med
ACC1-expressing pathogenic T helper 2 cell populations facilitate lung and skin inflammation in mice. [Abstract]2021 Dec 6;218(12):e20210639. PMID: 34813654 -
Cell Death Dis
A novel function of NLRP3 independent of inflammasome as a key transcription factor of IL-33 in epithelial cells of atopic dermatitis. [Abstract]2021 Sep 24;12(10):871. PMID: 34561424 -
J Cachexia Sarcopenia Muscle
2025 Feb;16(1):e13733. PMID: 39957010
Calcipotriol purchased from MedChemExpress. Usage Cited in: J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13733. [Abstract]
Calcipotriol (cal, 60 μg/kg; i.p., three times a week) decreases the proportion of fibres with a CSA of 200-400 μm2 and increases the proportion of fibres with a CSA of 1000-1400 μm2 in male SKO mice, whereas it does not affect female mice.
-
Proc Natl Acad Sci U S A
2023 Apr 4;120(14):e2221255120. PMID: 36972453 -
Int J Biol Macromol
Bacterial cellulose membrane integrating phase-transited lysozyme nanofilm loaded with biguanides for dressing treatment of atopic dermatitis. [Abstract]2025 Aug 21;323(Pt 1):147047. PMID: 40848785 -
Acta Pharmacol Sin
Differential regulation of pruritic sensation and emotion by cannabinoid type 1 receptors on mPFC glutamatergic and GABAergic neurons. [Abstract]2025 Apr;46(4):904-921. PMID: 39663420 -
Acta Pharmacol Sin
Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling. [Abstract]2023 Jan;44(1):178-188. PMID: 35676532
Calcipotriol purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Jan;44(1):178-188. [Abstract]
Calcipotriol (Cal, 500 µM; 24 h) significantly stimulates VDR activation in HGC27 and AGS cells, but not in CAFs.
-
Phytomedicine
Reversal of BCAA-driven inflammatory senescence by traditional herbal oil prevents atopic dermatitis relapse. [Abstract]2025 Oct 20:148:157425. PMID: 41161187 -
Phytomedicine
A tri-compound formula comprising Ginsenoside Rg1, tetrandrine and icariin alleviates atopic dermatitis symptoms in a mouse model. [Abstract]2025 Apr 7:141:156737. PMID: 40222169 -
Free Radic Biol Med
PN-CeO2 as a potential therapeutic agent for atopic dermatitis: Antioxidant and anti-inflammatory effects. [Abstract]2025 Nov:239:540-551. PMID: 40782974 -
J Transl Med
Bifidobacterium animalis subsp. Lactis BX-BC08 modulates gut microbiota and secretes alpha-Ketoglutaric acid to alleviate MC903-induced atopic dermatitis. [Abstract]2025 Jul 10;23(1):768. PMID: 40640914 -
Cell Rep
Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization. [Abstract]2023 Nov 13;42(11):113430. PMID: 37963021 -
Phytother Res
Sappanone A Exerted Strong Anti-Inflammatory Effects in the Treatment of Atopic Dermatitis Through IL-21R-Mediated JAK1/STAT3 Pathway. [Abstract]2025 Nov 14. PMID: 41236101 -
Cell Mol Life Sci
Guided monocyte fate to FRβ/CD163+ S1 macrophage antagonises atopic dermatitis via fibroblastic matrices in mouse hypodermis. [Abstract]2024 Dec 25;82(1):14. PMID: 39720957 -
J Invest Dermatol
An S100A8/A9 Neutralizing Antibody Potently Ameliorates Contact Hypersensitivity and Atopic Dermatitis Symptoms. [Abstract]2025 Aug;145(8):1930-1945.e3. PMID: 39848567 -
J Invest Dermatol
TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]2024 May 30:S0022-202X(24)00384-1. PMID: 38823435 -
J Invest Dermatol
Retracing from Outcomes to Causes: NRF2-Driven GSTA4 Transcriptional Regulation Controls Chronic Inflammation and Oxidative Stress in Atopic Dermatitis Recurrence. [Abstract]2024 Jun 13:S0022-202X(24)01735-4. PMID: 38879155 -
J Invest Dermatol
Mast cells Initiate Type 2 Inflammation via Tryptase Released by MRGPRX2/MrgprB2 Activation in Atopic Dermatitis. [Abstract]2024 Jan;144(1):53-62.e2. PMID: 37482287 -
J Invest Dermatol
Extracellular Vesicles of Commensal Skin Microbiota Alleviate Cutaneous Inflammation in Atopic Dermatitis Mouse Model by Re-Establishing Skin Homeostasis. [Abstract]2025 Feb;145(2):312-322.e9. PMID: 36907322 -
Biochem Pharmacol
Vitamin D receptor agonists inhibit liver fibrosis by disrupting the interaction between hepatic stellate cells and neutrophil extracellular traps. [Abstract]2025 Jun 24:240:117059. PMID: 40571206 -
J Ethnopharmacol
Elephantopus scaber suppresses ConA-induced T cell activation by inhibiting NF-κB and Ca2+/NFAT signaling. [Abstract]2026 May 10:362:121364. PMID: 41687940 -
J Ethnopharmacol
Elephantopus scaber attenuates MC903-caused atopic dermatitis and decreases TNF-α/IFN-γ-induced chemokines by suppressing MKP-1-mediated AP-1 signaling in keratinocytes. [Abstract]2025 Aug 29:352:120267. PMID: 40633861 -
J Ethnopharmacol
Calycosin enhances Treg differentiation for alleviating skin inflammation in atopic dermatitis. [Abstract]2024 May 23:326:117883. PMID: 38331120 -
Int J Pharm
FAP-targeting biomimetic nanosystem to restore the activated cancer-associated fibroblasts to quiescent state for breast cancer radiotherapy. [Abstract]2025 Jan 7:125190. PMID: 39788396 -
Int J Mol Sci
Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation. [Abstract]2017 Dec 19;18(12). pii: E2764. PMID: 29257109 -
Front Pharmacol
Schizonepeta tenuifolia Briq-Saposhnikovia divaricata decoction alleviates atopic dermatitis via downregulating macrophage TRPV1. [Abstract]2024 Aug 27:15:1413513. PMID: 39257398 -
Front Pharmacol
Calcipotriol Inhibits NLRP3 Signal Through YAP1 Activation to Alleviate Cholestatic Liver Injury and Fibrosis. [Abstract]2020 Mar 31;11:200. PMID: 32296329 -
Eur J Pharmacol
A multi-target combinatorial therapy of MDBA alleviates atopic dermatitis via synchronized immunosuppression and barrier repair. [Abstract]2026 Mar 28:1019:178729. PMID: 41802486 -
Int Immunopharmacol
Fecal microbiota transplantation affects the recovery of AD-skin lesions and enhances gut microbiota homeostasis. [Abstract]2023 May:118:110005. PMID: 36924566 -
Nanomedicine
Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. [Abstract]2017 May;13(4):1473-1482. PMID: 28259803 -
J Inflamm Res
Neural-Inflammation Mechanism of Spinal Palmitic Acid Promoting Atopic Dermatitis in Mice. [Abstract]2025 Jun 17:18:7907-7919. PMID: 40546406 -
J Integr Med
Prim-O-glucosylcimifugin mitigates atopic dermatitis by inhibiting Th2 differentiation through LCK phosphorylation modulation. [Abstract]2025 May;23(3):309-319. PMID: 40253253 -
Virol Sin
Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]2024 Aug 19:S1995-820X(24)00134-2. PMID: 39168248 -
Sci Rep
A subpopulation of projections from the parabrachial nucleus to the central amygdala mediates itch. [Abstract]2025 Jul 21;15(1):26432. PMID: 40691451 -
Cytokine
Calcipotriol suppresses GPX4-mediated ferroptosis in OA chondrocytes by blocking the TGF-β1 pathway. [Abstract]2023 Nov:171:156382. PMID: 37782985 -
Med Hypotheses
SARS-CoV-2 might transmit through the skin while the skin barrier function could be the mediator. [Abstract]2022 Feb:159:110752. PMID: 35002019 -
-
-
-
Solvent & Solubility
DMSO : 100 mg/mL (242.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (121.18 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Normal human epidermal keratinocytes (NHEK) are grown in serum-free keratinocyte growth medium Epilife and used at third passage in all experiments. Growth supplement is omitted 48 h before experiments. As a control, IL-17A and IL-22 are either added or not added to the cells. Cultured NHEK cells are stimulated with IL-17A (200 ng/mL) and/or IL-22 (200 ng/mL) followed by co-incubation in the presence or absence of Calcipotriol at 0.2-40 nM to test its modulatory effect. Cells are harvested 3 days later and subjected to real-time quantitative PCR (qPCR). Culture supernatants are also collected and frozen at -80°C until use for ELISA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[3]
The 160 female SKH-1 hairless mice (6-7 weeks of age) are used. After UV treatment, mice without tumors are randomly divided into five groups, four chemoprevention groups (Diclofenac plus DFMO; Diclofenac plus Calcipotriol; DFMO plus calcitriol; and Diclofenac plus DFMO plus Calcipotriol) and one placebo group (skin lotion). The placebo group used in this study is the same as the one used in an earlier study. The mice are treated with test mixtures once a day, five days a week, for a total of 17 weeks. The test mixtures are applied topically on the dorsal surface of the mice. Ten microliters are applied by a pipette after which the mixture is rubbed onto the skin. This corresponded to the following doses of each active substance in the treatments: 100 μg/week for Diclofenac (30 mg/g undiluted), 0.166 μg/week for Calcitriol (50 μg/g undiluted), and 463.3 μg/week for difluoromethylornithine (DFMO) (139 mg/g undiluted).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sakabe JI, et al. Calcipotriol Increases hCAP18 mRNA Expression but Inhibits Extracellular LL37 Peptide Production in IL-17/IL-22-stimulated Normal Human Epidermal Keratinocytes. Acta Derm Venereol. 2014 Sep;94(5):512-6. [Content Brief]
[2]. Al-Jaderi Z, et al. Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel). 2013 Oct 28;5(11):1932-47. [Content Brief]
[3]. Pommergaard HC, et al. Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res. 2013 Aug;33(8):3033-9. [Content Brief]
[5]. Kaur A, et al. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017 May;13(4):1473-1482. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.4237 mL | 12.1183 mL | 24.2365 mL | 60.5914 mL |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8473 mL | 12.1183 mL | |
| 10 mM | 0.2424 mL | 1.2118 mL | 2.4237 mL | 6.0591 mL | |
| 15 mM | 0.1616 mL | 0.8079 mL | 1.6158 mL | 4.0394 mL | |
| 20 mM | 0.1212 mL | 0.6059 mL | 1.2118 mL | 3.0296 mL | |
| 25 mM | 0.0969 mL | 0.4847 mL | 0.9695 mL | 2.4237 mL | |
| 30 mM | 0.0808 mL | 0.4039 mL | 0.8079 mL | 2.0197 mL | |
| 40 mM | 0.0606 mL | 0.3030 mL | 0.6059 mL | 1.5148 mL | |
| 50 mM | 0.0485 mL | 0.2424 mL | 0.4847 mL | 1.2118 mL | |
| 60 mM | 0.0404 mL | 0.2020 mL | 0.4039 mL | 1.0099 mL | |
| 80 mM | 0.0303 mL | 0.1515 mL | 0.3030 mL | 0.7574 mL | |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.6059 mL |